Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Sucampo Pharmaceuticals, Inc.    SCMP   US8649091068

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/24/2014 10/27/2014 10/28/2014 10/29/2014 10/30/2014 Date
8.31(c) 8.33(c) 8.35(c) 8.34(c) 8.66 Last
99 473 112 276 117 926 121 394 115 163 Volume
-1.31% +0.24% +0.24% -0.12% +3.84% Change
More quotes
Company
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company which engages in research, discovery, development and commercialization of proprietary drugs based on prostones and other novel drug technologies.Prostones are naturally occurring fatty acid metabolites with unique physiological... 
Surperformance© rating of Sucampo Pharmaceuticals, I
Trading Rating : Investor Rating :
More about the company
Chart SUCAMPO PHARMACEUTICALS, I
Duration : Period :
Sucampo Pharmaceuticals, I Technical Analysis Chart | SCMP | US8649091068 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 108 M
EBIT 2014 22,2 M
Net income 2014 8,27 M
Finance 2014 10,1 M
Yield 2014 -
Sales 2015 117 M
EBIT 2015 27,8 M
Net income 2015 19,2 M
Finance 2015 32,3 M
Yield 2015 -
PER 2014 47,49
PER 2015 20,05
EV / Sales 2014 3,32x
EV / Sales 2015 2,87x
Capitalization 369 M
More Financials
Latest news on SUCAMPO PHARMACEUTICALS, I
6d ago SUCAMPO PHARMACEUTICALS : Announces Third Quarter 2014 Earnings Call
10/23 SUCAMPO PHARMACEUTICALS : Solidifies Leadership Team With Additions of CSO and H..
10/21 SUCAMPO PHARMACEUTICALS : Takeda and Sucampo Enter Into Global Licensing Agreeme..
10/14 SUCAMPO PHARMACEUTICALS : Announces Extension of AMITIZA(R) (lubiprostone) Licen..
10/13 SUCAMPO PHARMACEUTICALS : Clinical Data for AMITIZA(R) Lubiprostone to be Presen..
10/09 Sucampo Announces Settlement Agreement That Resolves Patent Litigation in U.S..
10/06 SUCAMPO PHARMACEUTICALS : Announces Departure of Chief Financial Officer
09/29 SUCAMPO PHARMACEUTICALS : and Takeda Launch Direct-to-Consumer Advertising Campa..
09/17 SUCAMPO PHARMACEUTICALS : Change in Directors or Principal Officers (form 8-K)
08/21 SUCAMPO PHARMACEUTICALS : Entry into a Material Definitive Agreement, Terminatio..
08/21 SUCAMPO PHARMACEUTICALS : Announces New Exclusive Global Manufacturing and Suppl..
08/06 SUCAMPO PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
More news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF